Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provides optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

Bausch + Lomb Corporation

An update from Bausch + Lomb Corporation ( ($BLCO) ) is now available. Bausch + Lomb Corporation announced that its Chairman and CEO, Brent Saunder...

Bausch + Lomb to Engage at Citi Global Healthcare Conference

The latest update is out from Bausch + Lomb Corporation ( ($BLCO) ). On November 13, 2025, Bausch + Lomb Corporation announced its plans during an ...

Bausch + Lomb Unveils Strategic Growth Plan at Investor Day

In a report released today, Patrick Wood from Morgan Stanley maintained a Hold rating on Bausch + Lomb Corporation, with a price target of $14.00. ...

Bausch + Lomb Corporation (BLCO) Gets a Hold from Morgan Stanley

In a report released today, Matt Miksic from Barclays maintained a Hold rating on Bausch + Lomb Corporation, with a price target of $17.00. The com...

Bausch + Lomb Corporation (BLCO) Gets a Hold from Barclays

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bausch + Lomb Corporation (BLCO – Research Report)...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bausch + Lomb Corporation (BLCO), United Therapeutics (UTHR) and Unicycive Therapeutics (UNCY)

An announcement from Bausch + Lomb Corporation ( ($BLCO) ) is now available. Bausch + Lomb Corporation reported a revenue of $1.281 billion for the...

Bausch + Lomb Reports Q3 2025 Revenue Growth Amid Net Loss

Barclays analyst Matt Miksic maintained a Hold rating on Bausch + Lomb Corporation today and set a price target of $16.00. The company’s shares clo...

Current Quarter	$0.35	Next Quarter	$0.09
Current Year	$0.54	Next Year	$0.78
QoQ Growth	-74.3%	YoY Growth	+44.4%
3Y EPS CAGR	-585.6%	Target Price	$16.57
Consensus	Buy	Upside	+10.0%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BLCO	$15.07	+3.50%	403.23K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BLCO	$15.07	+3.5%	403.23K
3
4
5
6

BLCO

BLCO

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Bausch + Lomb Corporation Data in Excel

Get Bausch + Lomb Corporation Data in Excel